BioCentury | May 6, 2013
Company News

Diamyd Medical endocrine/metabolic, cancer, neurology news

...which was renamed Diamyd Medical AB, as part of a liquidation process announced in February. The former Diamyd Medical...
...to shareholders and convert all shares to one class. Additionally, shares in the newly named Diamyd Medical...
...Protein Sciences Corp. (Meriden, Conn.) and diagnostic company Mercodia AB (Uppsala, Sweden). The newly named Diamyd Medical...
BioCentury | Mar 4, 2013
Company News

Diamyd Medical endocrine/metabolic news

...million), to shareholders and convert all shares to one class. Additionally, shares in the subsidiary Diamyd Therapeutics...
...a recombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine (see BioCentury, Nov. 5, 2012). Diamyd Medical AB...
BioCentury | Feb 18, 2013
Company News

Diamyd Medical endocrine/metabolic news

...a recombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine (see BioCentury, Nov. 5, 2012). Diamyd Medical AB...
BioCentury | Feb 11, 2013
Financial News

Diamyd financial update

...has lapsed. The company, which closed at SEK12.10, on Friday, has 28.1 million shares outstanding. Diamyd Medical AB...
BioCentury | Feb 4, 2013
Clinical News

Diamyd: Phase II start

...the Phase II DiAPREV-IT trial to prevent Type I diabetes (see BioCentury, Jan. 16, 2012). Diamyd Medical AB...
BioCentury | Dec 17, 2012
Financial News

Diamyd financial update

...B shares. The company, which closed at SEK9.95 on Friday, has 29.6 million shares outstanding. Diamyd Medical AB...
BioCentury | Dec 3, 2012
Financial News

Diamyd financial update

...at SEK12. The company, which closed at SEK9.60 on Friday, has 28.1 million shares outstanding. Diamyd Medical AB...
BioCentury | Nov 5, 2012
Company News

Diamyd Medical endocrine/metabolic news

...million ($56.8 million) in cash and a nine-month operating loss of SEK34.2 million ($4.7 million). Diamyd Medical AB...
BioCentury | Oct 15, 2012
Company News

Diamyd Medical, Periphagen Holdings deal

...HSV) vector delivering the enkephalin gene using NTTDS in Phase II testing for cancer pain. Diamyd Medical AB...
BioCentury | Jul 9, 2012
Clinical News

NP2 Enkephalin: Phase II data

...NTDDS candidates include the preclinical pain products NG2 glutamic acid decarboxylase (GAD) and NE2 Endomorphin. Diamyd Medical AB...
Items per page:
1 - 10 of 93
BioCentury | May 6, 2013
Company News

Diamyd Medical endocrine/metabolic, cancer, neurology news

...which was renamed Diamyd Medical AB, as part of a liquidation process announced in February. The former Diamyd Medical...
...to shareholders and convert all shares to one class. Additionally, shares in the newly named Diamyd Medical...
...Protein Sciences Corp. (Meriden, Conn.) and diagnostic company Mercodia AB (Uppsala, Sweden). The newly named Diamyd Medical...
BioCentury | Mar 4, 2013
Company News

Diamyd Medical endocrine/metabolic news

...million), to shareholders and convert all shares to one class. Additionally, shares in the subsidiary Diamyd Therapeutics...
...a recombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine (see BioCentury, Nov. 5, 2012). Diamyd Medical AB...
BioCentury | Feb 18, 2013
Company News

Diamyd Medical endocrine/metabolic news

...a recombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine (see BioCentury, Nov. 5, 2012). Diamyd Medical AB...
BioCentury | Feb 11, 2013
Financial News

Diamyd financial update

...has lapsed. The company, which closed at SEK12.10, on Friday, has 28.1 million shares outstanding. Diamyd Medical AB...
BioCentury | Feb 4, 2013
Clinical News

Diamyd: Phase II start

...the Phase II DiAPREV-IT trial to prevent Type I diabetes (see BioCentury, Jan. 16, 2012). Diamyd Medical AB...
BioCentury | Dec 17, 2012
Financial News

Diamyd financial update

...B shares. The company, which closed at SEK9.95 on Friday, has 29.6 million shares outstanding. Diamyd Medical AB...
BioCentury | Dec 3, 2012
Financial News

Diamyd financial update

...at SEK12. The company, which closed at SEK9.60 on Friday, has 28.1 million shares outstanding. Diamyd Medical AB...
BioCentury | Nov 5, 2012
Company News

Diamyd Medical endocrine/metabolic news

...million ($56.8 million) in cash and a nine-month operating loss of SEK34.2 million ($4.7 million). Diamyd Medical AB...
BioCentury | Oct 15, 2012
Company News

Diamyd Medical, Periphagen Holdings deal

...HSV) vector delivering the enkephalin gene using NTTDS in Phase II testing for cancer pain. Diamyd Medical AB...
BioCentury | Jul 9, 2012
Clinical News

NP2 Enkephalin: Phase II data

...NTDDS candidates include the preclinical pain products NG2 glutamic acid decarboxylase (GAD) and NE2 Endomorphin. Diamyd Medical AB...
Items per page:
1 - 10 of 93